Glenmark Pharma

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

As of 15-Jun, Glenmark Pharmaceuticals Ltd. is experiencing a stock price decline to 2,155.60, down 0.81%, following two days of gains. Despite strong fundamentals, the stock is underperforming against the Sensex and showing bearish short-term trends.

As of 15-Jun, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at 2,155.60, which reflects a change of -17.6 or -0.81%. This downward movement is notable as it follows two consecutive days of gains, indicating a trend reversal. The stock has underperformed against the benchmark Sensex, which has risen by 3.73% over the past week, while Glenmark's stock has fallen by 1.05% in the same period. <BR><BR>Investor participation appears to be decreasing, as evidenced by a drop in delivery volume by 9.55% against the five-day average. Additionally, while the stock is trading above its 200-day moving averages, it is below the shorter-term moving averages of 5, 20, 50, and 100 days, suggesting a bearish sentiment in the short term. <BR><BR>Despite these negative indicators, the company has strong fundamentals, including a low Debt to EBITDA ratio of 0.13 times and positive financial results over the last three quarters. However, the current market reaction seems to be overshadowing these strengths, contributing to the stock's decline.

Which are the latest news on Glenmark Pharma?

What does Glenmark Pharma do?

Glenmark Pharmaceuticals Ltd. is a mid-cap company engaged in the discovery, development, manufacture, and marketing of pharmaceutical products, with a market cap of INR 62,304 Cr and a net profit of 301 Cr for the quarter ending March 2026.

Overview: <BR>Glenmark Pharmaceuticals Ltd. is a mid-cap company in the Pharmaceuticals & Biotechnology industry, actively involved in the discovery, development, manufacture, and marketing of pharmaceutical products.<BR><BR>History: <BR>Glenmark Pharmaceuticals Ltd. was incorporated on November 18th, 1977. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 3,771 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 301 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 62,304 Cr (Mid Cap) <BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.23% <BR>Debt Equity: -0.06 <BR>Return on Equity: 26.86% <BR>Price to Book: 5.91 <BR><BR>Contact Details: <BR>Address: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road Mumbai Maharashtra : 400026 <BR>Tel: 91-22-40189999 <BR>Email: complianceofficer@glenmarkpharma.co <BR>Website: http://www.glenmarkpharma.com

How big is Glenmark Pharma?

As of 10th June, Glenmark Pharmaceuticals Ltd. has a market capitalization of 62,304.00 Cr, with recent net sales of 16,982.52 Cr and a net profit of 1,361.84 Cr.

As of 10th June, Glenmark Pharmaceuticals Ltd. has a market capitalization of 62,304.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Glenmark Pharma reported Net Sales of 16,982.52 Cr and a Net Profit of 1,361.84 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 8,849.44 Cr and Total Assets valued at 14,925.44 Cr.

Who are in the management team of Glenmark Pharma?

The management team of Glenmark Pharma includes Glenn Saldanha (Chairman/Executive Director), Cheryl Pinto (Executive Director), and V S Mani (Executive Director & Group CFO), along with several independent and non-executive directors who guide the company's strategic direction.

The management team of Glenmark Pharma includes the following key individuals:<BR><BR>1. **Glenn Saldanha** - Chairman / Executive Director<BR>2. **Cheryl Pinto** - Executive Director (Corporate)<BR>3. **V S Mani** - Executive Director & Group CFO<BR><BR>Additionally, the Board of Directors features several independent and non-executive directors:<BR><BR>- **B E Saldanha** - Non Executive Director<BR>- **Rajesh Desai** - Independent Non Executive Director<BR>- **Devendra Raj Mehta** - Independent Non Executive Director<BR>- **Bernard Munos** - Independent Non Executive Director<BR>- **Brian W Tempest** - Independent Non Executive Director<BR>- **Sridhar Gorthi** - Independent Non Executive Director<BR>- **Sona Saira Ramasastry** - Independent Non Executive Director<BR>- **Dipankar Bhattacharjee** - Independent Non Executive Director<BR>- **V R Iyer** - Independent Non Executive Director<BR><BR>This team plays a crucial role in guiding the company’s strategic direction and operations.

Who are the peers of the Glenmark Pharma?

Glenmark Pharma's peers include Mankind Pharma, Aurobindo Pharma, Biocon, and others. In terms of management risk, growth, and capital structure, Mankind Pharma and Anthem Bioscienc show excellent performance, while Glenmark Pharma has average growth and good management risk.

Peers: Glenmark Pharma's peers include Mankind Pharma, Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, Abbott India, Anthem Bioscienc, Ipca Labs, Gland Pharma, and Ajanta Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Mankind Pharma, Abbott India, Anthem Bioscienc, and Ajanta Pharma, while Average management risk is found at Aurobindo Pharma and Biocon. Good management risk is noted at Laurus Labs, Alkem Lab, Glenmark Pharma, Ipca Labs, Gland Pharma, and the rest. For growth, Excellent growth is seen at Mankind Pharma and Anthem Bioscienc, while Average growth is found at Glenmark Pharma and Abbott India. Below Average growth is noted at Aurobindo Pharma, Laurus Labs, Biocon, Alkem Lab, Ipca Labs, Gland Pharma, and the rest. In terms of Capital Structure, Excellent capital structure is observed at Aurobindo Pharma, Mankind Pharma, Alkem Lab, Abbott India, Anthem Bioscienc, Ipca Labs, Gland Pharma, and the rest, while Average capital structure is noted at Laurus Labs, and Below Average capital structure is seen at Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.68%, while Abbott India has the lowest at -16.68%, with Glenmark Pharma's 1-year return at 31.72%, indicating a significantly better performance than Abbott India. Additionally, Alkem Lab and Abbott India are among the peers with negative six-month returns.

Are Glenmark Pharmaceuticals Ltd. latest results good or bad?

Glenmark Pharmaceuticals Ltd.'s latest results show strong year-on-year growth with a net profit increase of 6,381.94% and net sales up 15.80%. However, there are concerns due to sequential declines in both profit and sales, indicating potential volatility in performance.

Glenmark Pharmaceuticals Ltd.'s latest results present a mixed picture. For the quarter ending March 2026, the company reported a net profit of ₹301.41 crores, which reflects a significant year-on-year increase of 6,381.94%. However, this represents a decline of 25.25% compared to the previous quarter, raising concerns about the sustainability of its recent performance.<BR><BR>Net sales for the same quarter were ₹3,770.59 crores, showing a 15.80% increase year-on-year, but a decrease of 3.33% from the previous quarter. This sequential decline follows an unusually strong performance in Q3 FY26, which had benefited from one-time gains.<BR><BR>Operating margins also contracted to 20.28%, down from 22.37% in the previous quarter, indicating some pressure on profitability. Despite these challenges, the company's return on capital employed (ROCE) reached an impressive 40.16%, the highest level recorded in recent periods, suggesting strong operational efficiency.<BR><BR>Overall, while Glenmark's year-on-year growth is commendable, the sequential declines in both net profit and sales indicate potential volatility and questions about the underlying business momentum. Investors may want to consider these factors when evaluating the company's performance.

Should I buy, sell or hold Glenmark Pharmaceuticals Ltd.?

When is the next results date for Glenmark Pharmaceuticals Ltd.?

The next results date for Glenmark Pharmaceuticals Ltd. is 29 May 2026.

The next results date for Glenmark Pharmaceuticals Ltd. is scheduled for 29 May 2026.

Is Glenmark Pharma overvalued or undervalued?

As of November 17, 2025, Glenmark Pharma is considered undervalued with a PE ratio of 23.47 and strong growth potential, outperforming peers like Sun Pharma and Cipla, and has delivered a 21.44% return over the past year compared to the Sensex's 9.50%.

As of 17 November 2025, Glenmark Pharma's valuation grade has moved from expensive to attractive, indicating a shift in market perception. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 23.47, an EV to EBITDA of 12.50, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Glenmark Pharma's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 36.69, while Cipla, another attractive peer, has a PE of 22.81. This positions Glenmark favorably within the industry, particularly given its robust ROCE of 44.14% and ROE of 23.46%. Additionally, Glenmark's stock has outperformed the Sensex over the past year, with a return of 21.44% compared to the Sensex's 9.50%, reinforcing the attractiveness of its current valuation.

How has been the historical performance of Glenmark Pharma?

Glenmark Pharma's historical performance shows significant fluctuations, with net sales increasing to 13,321.74 Cr in Mar'25 after a dip in Mar'23, and a recovery in profit after tax to 1,047.14 Cr in Mar'25 from a loss of 1,830.85 Cr in the previous year. Despite negative cash flow from operating activities in Mar'25, the company demonstrates a recovery trajectory following a challenging period.

Answer:<BR>The historical performance of Glenmark Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Glenmark Pharma's net sales increased from 10,640.97 Cr in Mar'20 to 13,321.74 Cr in Mar'25, with a notable dip in Mar'23 at 12,990.11 Cr. Total operating income followed a similar trend, reaching 13,321.74 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 8,279.66 Cr in Mar'19 to 10,970.36 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 2,595.16 Cr in Mar'23 before declining to 2,465.10 Cr in Mar'25. Profit before tax was 1,399.21 Cr in Mar'25, recovering from a low of 36.50 Cr in Mar'24. The profit after tax turned positive at 1,047.14 Cr in Mar'25 after a significant loss of 1,830.85 Cr in the previous year. The earnings per share (EPS) rebounded to 37.1 in Mar'25 from a negative EPS of -53.21 in Mar'24. Total assets increased to 14,925.44 Cr in Mar'25, while total liabilities also rose to 14,925.44 Cr, indicating a balanced growth in the company’s financial structure. Cash flow from operating activities was negative at -827.00 Cr in Mar'25, contrasting with a positive cash flow of 782.00 Cr in Mar'24. Overall, Glenmark Pharma's financial performance reflects a recovery trajectory in 2025 after a challenging previous year.

Is Glenmark Pharma technically bullish or bearish?

As of September 10, 2025, Glenmark Pharma's trend is mildly bullish, supported by daily moving averages and weekly Bollinger Bands, but tempered by mixed signals from the MACD and OBV.

As of 10 September 2025, the technical trend for Glenmark Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum and the weekly Bollinger Bands also showing bullish signals. However, the weekly MACD is mildly bearish and the KST is bullish on a weekly basis but mildly bearish on a monthly basis, suggesting some mixed signals. The Dow Theory indicates a mildly bullish stance on the weekly chart, while the OBV shows a mildly bearish trend. Overall, the strength of the bullish sentiment is tempered by the mixed indicators, particularly on the weekly timeframe.

Who are the top shareholders of the Glenmark Pharma?

The top shareholders of Glenmark Pharma include the Saldanha Family Trust with 45.45%, institutional investors holding 36.02% (including 25 mutual fund schemes at 12.86% and 347 FIIs at 23.16%), and individual investors with 12.32%. HDFC Mutual Fund is the largest public shareholder with a 4.27% stake.

The top shareholders of Glenmark Pharma include the Saldanha Family Trust, which holds the largest stake at 45.45%. The company also has significant institutional backing, with 25 mutual fund schemes collectively holding 12.86% and 347 foreign institutional investors (FIIs) holding 23.16%. Additionally, HDFC Mutual Fund, specifically through the HDFC Nifty Large Midcap 250 Index fund, is the highest public shareholder with a 4.27% stake. Individual investors collectively own 12.32% of the company.

Has Glenmark Pharma declared dividend?

Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly in the long term.

Glenmark Pharmaceuticals Ltd. has declared a 250% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 3.97%, with no dividend return, resulting in a total return of 3.97%.<BR><BR>Over the past year, the price return was 31.68%, with a dividend return of 0.21%, leading to a total return of 31.89%.<BR><BR>In the 2-year period, the price return was 152.58%, with a dividend return of 0.78%, culminating in a total return of 153.36%.<BR><BR>For the 3-year period, the price return was 305.84%, with a dividend return of 2.04%, resulting in a total return of 307.88%.<BR><BR>In the last 4 years, the price return was 159.41%, with a dividend return of 1.50%, giving a total return of 160.91%.<BR><BR>Over the 5-year period, the price return was 295.81%, with a dividend return of 2.87%, leading to a total return of 298.68%.<BR><BR>Overall, Glenmark Pharma has declared a substantial dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting a positive performance trend for the company.